On January 7, 2021, BENEV Company, Inc., an FDA-registered cosmeceutical manufacturer of a globally recognized medical professional line, along with its Medical Advisory Board comprised of five global medical leaders, announced that that the 12-week Prospective, Double-Blind, Randomized, Split-Face Investigative Report on Combination Treatment with Human Adipose Tissue Stem Cell-Derived Exosomes and Fractional CO2 Laser for Acne Scars by ExoCoBio Inc., an equity-invested partner of BENEV, was published online on October 19, 2020, in Acta Dermato-Venereologica (https://www.medicaljournals.se/acta/content_files/files/pdf/100/18/5913.pdf). This open-access report outlines the investigative study that was conducted by a team of scientists and physicians including Hyuck Hoon Kwon, Steven Hoseong Yang, Joon Lee, Byung Chul Park, Kui Young Park, Jae Yoon Jung, Youin Bae, and Gyeong-Hun at Oaro Dermatology Institute (Seoul, South Korea); Guam Dermatology Institute (Guam, USA); Department of Dermatology, Dankook University, College of Medicine (Cheonan, South Korea); Department of Dermatology, Chung-Ang University, College of Medicine (Seoul, South Korea); and the Department of Dermatology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine (Hwaseong, South Korea). Researchers involved in this study evaluated the clinical efficacy and safety of adipose tissue stem cell-derived exosomes as an adjuvant therapy after application of fractional CO2 laser for acne scars. 25 patients consisting of 18 men and 7 women, between ages 19 and 54, 12 with Fitzpatrick Skin Type 3 and 13 with Fitzpatrick skin type 4 and atrophic acne scars, underwent the 12-week prospective, double-blind, randomized, split-face trial.
Login Or Register To Read Full Story